HPV vaccination crisis in Japan
Free vaccination against the human papillomavirus (HPV) began in December, 2010, for Japanese girls aged 12-16 years and since April, 2013, the vaccine was included in the national immunisation programme. However, in June, 2013, the Japanese Ministry of Health, Labour, and Welfare suspended proactive recommendations for the HPV vaccine after unconfirmed reports of adverse events following vaccination appeared in the media. 1 In January, 2014, the Vaccine Adverse Reactions Review Committee investigating these adverse events concluded that there was no evidence to suggest a causal association between the HPV vaccine and the reported adverse events after vaccination, but they still did not reinstate proactive recommendations for its use. 2 We report the resulting effects of such a decision by presenting data from Sapporo, a city of 2 million people in northern Japan. Before public funding was intro duced, we investigated correlates of HPV vaccine acceptance in mothers with adolescent daughters living in Sapporo. Although cost was a large barrier, with only 1·5% of parents willing to pay the full vaccine price, recommendation from a physician was a strong motivator (odds ratio 12·2, 95% CI 7·1-21·1). 3 In the years between becoming free (2011 in Sapporo) and before the suspension of recommendations (2013), rates of HPV vaccination in Sapparo ranged from 73·6-77·2% at initiation and 68·4-74·0% for three dose completion in girls in the 1994-98 birth cohorts (fi gure). However, in the fi rst birth cohort of 7705 girls eligible for vaccination after suspension, completion rates plummeted to just 0·6%, with only 49 girls fi nishing the dosing course despite the vaccine still being part of the national immunisation programme and free.
We believe that Japan, whose uptake rates for cervical cancer screening have stag nated at about 30%, might have lost a real opportunity to decrease morbidity and mortality associated with cervical cancer. Other countries with successful HPV vaccination programmes (such as Australia and the UK), who have also dealt with similar adverse event crises, are already documenting substantial reductions in precancerous cervical lesions in those vaccinated. 4,5 
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For the Global Advisory Committee on Vaccine Safety's statement on HPV vaccination see http://www. who.int/vaccine_safety/ committee/topics/hpv/GACVS_ Statement_HPV_12_Mar_2014. pdf
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